SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis quarterly earnings report and forward guidance are the dominant focus, with traders watching whether growth and an improved outlook can change the stocks weak performance. Sentiment is sharply divided: some expect a rebound on strong results, while others fear another selloff even if the company beats expectations, citing past post-earnings declines and concerns about guidance.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas strong quarterly results and sharply raised outlook, including an ambitious 2027 revenue forecast, are driving attention amid demand for AI data-center hardware and networking. Bulls see the report as evidence the buildout remains robust, while skeptics point to margin and cash-flow concerns, high expectations, and volatile trading after a steep pullback.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced earnings outlook, and dividend suspension are driving attention, with management citing recession-level appliance demand and prioritizing debt reduction. Traders are split between fears over the balance sheet and a prolonged downturn, and bargain-hunting hopes for a rebound; many also question managements explanation and execution.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XPs sharp selloff is being linked to a broad rout in Brazilian assets after Lulas reelection, amid trader concerns about government spending, fiscal discipline and the currency. Many traders call the drop an overreaction and look for a rebound, while others warn that political and macroeconomic risks could keep pressure on the shares.

StoneCo Ltd. engages in the provision of financial technology solutions. It caters to merchants and partners that conduct electronic commerce across in-store, online, and mobile channels. The firm offers cloud-based technology platform, electronic payments, and automation of business processes at the point-of-sale. The company was founded by André Street de Aguiar in 2000 and is headquartered in São Paulo, Brazil.

StoneCo Ltd - Ordinary Shares - Class A

StoneCo Ltd

StoneCo is caught in a sharp selloff across Brazilian stocks after Lulas election win, as traders worry about fiscal discipline and the outlook for Brazilian assets. Some see the drop as an overreaction and a buying opportunity, while others are wary of further losses and are waiting for the market to find a floor.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Reported advanced acquisition talks with DoorDash are driving attention, with traders weighing the prospect of a takeover premium against claims that the offer undervalues Instacart and concerns that talks could fall through. No definitive deal has been announced.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

CEO John Giamatteos CNBC appearance highlighting QNXs expansion into physical AI and robotics, Alloy Kore, and its Nvidia collaboration is driving attention. Bulls see potential for BlackBerrys growth story to gain recognition, while skeptics question adoption and cite insider selling and market volatility.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention as small caps show resilience and traders debate whether recent strength signals a rotation out of AI and megacap tech. Some see easing-yield expectations and a potential catch-up rally as supportive, while others warn that weak breadth, technical resistance, and oil and Fed uncertainty could leave the bounce vulnerable.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is drawing attention ahead of its quarterly results, with traders focused on branded-checkout growth, margins and guidance; bearish voices fear another post-earnings drop and continued competitive pressure, while bulls point to subdued expectations and potential growth from Venmo and advertising. Takeover and bank-charter speculation is also circulating, but remains unconfirmed.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Reports that Volkswagen is weighing Xpeng-developed software for many European models have raised concern among traders about the RivianVW software partnership, as RIVN sinks to fresh 52-week lows. The discussion is also focused on upcoming quarterly results: bearish views cite cash burn and uncertain profitability, while some traders are buying the dip and looking for evidence of improving deliveries or margins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rocket Pharmaceuticals to Participate in Chardans 10th Annual Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardans 10th Annual Healthcare...

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update...

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with...

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.read more...

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Equity

Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.


Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on...

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Inc

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>Needham upgraded Rocket Pharmaceuticals to ‘Buy’ from ‘Hold’ with a $9 price target, according to The Fly.</li><li>The FDA said that Rocket could continue enrolling and dosing patients in the Phase 2 study at a recalibrated dose.</li><li>Last year, the FDA placed the study on clinical hold after one patient died from complications related to capillary leak syndrome.</li></ul>Rocket Pharmaceuticals (RCKT) was on investors’ radar on Wednesday after the biotech firm received an upgrade from Needham following its alignment with the U.S. Food and Drug Administration on a pivotal study for its experimental genetic disease therapy.Needham upgraded Rocket Pharma to ‘Buy’ from ‘Hold’ with a $9 price target, according to The Fly. This implies an upside of around 150% from current levels. The stock has a consensus 12-month price target of $8.84, according to Koyfin data, while six of the 14 analysts covering the stock have rated it a ‘Buy,’ six ‘Hold,’ and two ‘Sell.’At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> was up 7.6% and was on track for its best day so far this month.<h2 class="st-heading-2">Needham Says FDA Outcome Was Better Than Expected</h2>On Tuesday, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/rocket-pharma-gets-fda-alignment-on-this-key-trial-a-look-at-some-key-highlights/cZtnQJVRBcO">confirmed</a> that Rocket can continue enrolling and dosing patients in the Phase 2 study of RP-A501 at a recalibrated dose. The firm is testing its therapy on patients with Danon Disease, a rare, inherited genetic disorder that can cause severe damage to the heart and muscles. Rocket expects to complete dosing by mid-2027.The study will assess patients after 12 months to determine whether the treatment increases LAMP2 protein levels in the heart and reduces abnormal heart muscle thickness by at least 10%. The results could support a potential accelerated FDA approval.Needham said the FDA update removed a “meaningful regulatory overhang,” adding that the outcome was better than expected because regulators could have demanded meaningful changes to the study.<h2 class="st-heading-2">Why The FDA Decision Matters</h2>Last year, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp?">placed</a> the study on clinical hold after two patients experienced serious complications related to capillary leak syndrome, with one patient dying following an acute systemic infection. The FDA lifted the hold in August, allowing the study to resume at a lower recalibrated dose.<h2 class="st-heading-2">Retail’s Take On RCKT</h2>Retail sentiment surrounding RCKT on Stocktwits turned ‘neutral’ from ‘bearish’ over the past 24 hours, amid an 800% surge in message volume.One user pointed out that the “key efficacy catalyst” could be more than two years away.<stembedurl>https://stocktwits.com/Teillbou/message/664262402</stembedurl>RCKT shares have climbed around 2% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/nvo-to-present-fresh-data-from-blockbuster-wegovy-pill-at-european-conference-as-rival-eli-lilly-readies-its-own-obesity-updates/cZtYgMZRB2q">&nbsp;NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.

SPDR S&P Biotech ETF

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$2.28
Prev Close	$2.29
Open	$2.29
Dividend Yield	0.00%
50-Day Moving Average	$3.04
Beta	1.14
Avg. Volume	1.79M
PE Ratio	-12.66

52-Week High	$5.45
52-Week Low	$2.17
Market Capitalization	$250.29M
EPS (Annual)	-$2.01
Price to Book	0.68
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCKT Fundamentals